{"@id":"https://bioecon.ru/technology/o-glcnacase-inhibitors/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://cn.bioecon.ru/technology/o-glcnacase-inhibitors/","json":"https://cn.bioecon.ru/api/v1/technology/o-glcnacase-inhibitors/index.json"},"id":"o-glcnacase-inhibitors","industries":["pharma","biomanufacturing"],"lang":"cn","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/vci-technology-sdn-bhd/","https://bioecon.ru/companies/atomwise/","https://bioecon.ru/companies/fytofend/","https://bioecon.ru/companies/brain-biotech/","https://bioecon.ru/companies/evogene/","https://bioecon.ru/companies/tilak-paints/","https://bioecon.ru/companies/zero-cow-factory/","https://bioecon.ru/companies/insilico-medicine/","https://bioecon.ru/companies/microbika/","https://bioecon.ru/companies/shenzhen-siyomicro-bio-tech/"]},"maturity":7,"name":"O-GlcNAc糖苷酶（OGA）小分子抑制剂","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"催化过渡态模拟物分子理性设计"},{"n":2,"title":"血脑屏障被动穿透与非外排优化"},{"n":3,"title":"体内Tau蛋白病理性聚集阻断确证"},{"n":4,"title":"临床正电子发射断层显像（PET）靶点占位"}],"summary":"具备高度血脑屏障穿透能力的过渡态类似物O-GlcNAc糖苷酶（OGA）小分子抑制剂，通过提升神经元Tau蛋白与α-突触核蛋白的保护性糖基化修饰，从物理上阻断病理性神经原纤维缠结形成。","url":"/technology/o-glcnacase-inhibitors/","verified":"2026-11-22"}